×
News Home

Does BELLUS Health Inc (BLU) Have What it Takes to be in Your Portfolio?

Tuesday, November 24, 2020 01:42 PM | InvestorsObserver Analysts
Does BELLUS Health Inc (BLU) Have What it Takes to be in Your Portfolio?

BELLUS Health Inc (BLU) is near the middle in its industry group according to InvestorsObserver. BLU gets an overall rating of 46. That means it scores higher than 46 percent of stocks. BELLUS Health Inc gets a 51 rank in the Biotechnology industry. Biotechnology is number 40 out of 148 industries.

Overall Score - 46
BLU has an Overall Score of 46. Find out what this means to you and get the rest of the rankings on BLU!

What do These Ratings Mean?

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 46 would rank higher than 46 percent of all stocks.

These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

What's Happening With BELLUS Health Inc Stock Today?

BELLUS Health Inc (BLU) stock is down -0.83% while the S&P 500 has risen 1.57% as of 1:40 PM on Tuesday, Nov 24. BLU is lower by -$0.03 from the previous closing price of $3.02 on volume of 1,998,735 shares. Over the past year the S&P 500 has gained 15.96% while BLU is lower by -57.26%. BLU lost -$0.60 per share the over the last 12 months.

Click Here to get the full Stock Score Report on BELLUS Health Inc (BLU) Stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App